Linked Life Data

3226722

Source:http://linkedlifedata.com/resource/pubmed/id/3226722

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1989-3-28
pubmed:abstractText
Amplification of the c-erbB-2 proto-oncogene was detected in 10% of 122 primary human breast tumors examined. Examination of patients' histories with a post-surgical median follow-up time of 53 months suggested no statistically significant association between the increased copy number of c-erbB-2 proto-oncogene in breast tumors and several oncological disease parameters, such as histopathological grading, ovarian hormonal status, age, number of positive lymph nodes, time to relapse, and survival period. Results of the analysis of matched sets of primary tumors and lymph node metastases were also consistent with the lack of a strong association between increased copy number of c-erbB-2 proto-oncogene and aggressiveness of tumors.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0890-6467
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
139-46
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma.
pubmed:affiliation
Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland 20892.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't